◎ Sugi Atlas

Atlas / Drug / Olaratumab

Olaratumab

drug
On this page

Also known as IMC-3G3IMC3G3Lartruvo

Summary

Olaratumab (CHEMBL1743049) is an approved antibody (ATC L01FX10) targeting PDGFRA; indicated across 11 conditions including sarcoma and neoplasm.

At a glance

  • Status: Approved (max clinical phase 4)
  • Modality: Antibody
  • ATC class: L01FX10
  • Targets: 1 (PDGFRA)
  • Indications: 11 conditions
  • Clinical trials: 21

Identifiers

Drug identity and classification

FieldValue
ChEMBL IDCHEMBL1743049
NameOlaratumab
TypeAntibody
Max phase4
ATCL01FX10

Also known as: IMC-3G3, IMC3G3, Lartruvo, Olaratumab, OLARATUMAB

Targets

Targets

Primary targets (GtoPdb curated mechanism): the Cancer dependency column is the DepMap CRISPR fitness signal (% of screened cell lines dependent on the target).

GeneTargetActionpAffinityCancer dependencyUniProt
PDGFRAplatelet derived growth factor receptor alphaBinding10.46.2%P16234

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

Aggregated over 1 target gene(s): PDGFRA.

Top Reactome pathways

13 total, by targets touching each:

PathwayTargetsGenes
PIP3 activates AKT signaling1PDGFRA
Downstream signal transduction1PDGFRA
Signaling by PDGF1PDGFRA
Constitutive Signaling by Aberrant PI3K in Cancer1PDGFRA
RAF/MAP kinase cascade1PDGFRA
PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling1PDGFRA
Signaling by PDGFRA transmembrane, juxtamembrane and kinase domain mutants1PDGFRA
Signaling by PDGFRA extracellular domain mutants1PDGFRA
Imatinib-resistant PDGFR mutants1PDGFRA
Sunitinib-resistant PDGFR mutants1PDGFRA
Regorafenib-resistant PDGFR mutants1PDGFRA
Sorafenib-resistant PDGFR mutants1PDGFRA
PDGFR mutants bind TKIs1PDGFRA

Dominant GO biological processes

GO termTargets
luteinization1
in utero embryonic development1
cell activation1
hematopoietic progenitor cell differentiation1
cell surface receptor protein tyrosine kinase signaling pathway1
estrogen metabolic process1
positive regulation of cell population proliferation1
negative regulation of platelet activation1
cell migration1
peptidyl-tyrosine phosphorylation1
signal transduction involved in regulation of gene expression1
extracellular matrix organization1
lung development1
adrenal gland development1
positive regulation of cell migration1

Indications & clinical

Indications

3 approved indications. FDA phase 4, plus an anticancer drug’s labelled cancer uses (which ChEMBL often logs at phase 3).

IndicationPhaseMONDOEFO
sarcoma4MONDO:0005089EFO:0000691
neoplasm4MONDO:0005070EFO:0000616
soft tissue sarcoma4MONDO:0018078EFO:1001968

6 diseases in clinical trials (phase 1–3, investigational — not approved indications). Highest ChEMBL trial phase per disease; a non-cancer approved use is occasionally logged at phase 3 here.

Disease (in trials)PhaseMONDOEFO
non-small cell lung carcinoma2MONDO:0005233EFO:0003060
ovarian neoplasm2MONDO:0021068EFO:0003893
gastrointestinal stromal tumor2MONDO:0011719MONDO:0011719
glioblastoma2MONDO:0018177MONDO:0020690
leiomyosarcoma1MONDO:0005058EFO:0000564
exocrine pancreatic carcinoma1MONDO:0005192EFO:0002618

2 further indication records had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 21.

Phase distribution

PhaseTrials
PHASE110
PHASE26
PHASE1/PHASE23
PHASE31
Not specified1

Top trials by phase / activity

NCTPhaseStatusTitle
NCT02451943PHASE3COMPLETEDA Study of Doxorubicin Plus Olaratumab (LY3012207) in Participants With Advanced or Metastatic Soft Tissue Sarcoma
NCT00895180PHASE2COMPLETEDRamucirumab or Anti-PDGFR Alpha Monoclonal Antibody IMC-3G3 in Treating Patients With Recurrent Glioblastoma Multiforme
NCT00913835PHASE2COMPLETEDA Study of Liposomal Doxorubicin With or Without Olaratumab (IMC-3G3) in Platinum-Refractory or Resistant Advanced Ovarian Cancer
NCT00918203PHASE2COMPLETEDA Study of Paclitaxel/Carboplatin With or Without Olaratumab (IMC-3G3) in Previously Untreated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
NCT01185964PHASE1/PHASE2COMPLETEDA Study of Olaratumab in Soft Tissue Sarcoma
NCT01204710PHASE2COMPLETEDA Study of Olaratumab (IMC-3G3) in Prostate Cancer
NCT01316263PHASE2TERMINATEDA Study of Olaratumab (IMC-3G3) in Previously Treated Participants With Unresectable and/or Metastatic Gastrointestinal Stromal Tumors
NCT02659020PHASE1/PHASE2COMPLETEDA Study of Olaratumab (LY3012207) in Participants With Advanced Soft Tissue Sarcoma
NCT03086369PHASE1/PHASE2COMPLETEDA Study of Nab-Paclitaxel and Gemcitabine With or Without Olaratumab (LY3012207) in Participants With Metastatic Pancreatic Cancer
NCT03698227PHASE2TERMINATEDOlaReDo - Olaratumab and Rechallenge With Doxorubicin in Soft Tissue Sarcoma Patients
NCT00768391PHASE1COMPLETEDStudy of IMC-3G3 in Patients With Tumors That Are Not Responding to Standard Therapies or No Therapy is Available
NCT01199822PHASE1COMPLETEDStudy of the Safety and Pharmacokinetics of Olaratumab (IMC-3G3) in Japanese Participants With Solid Tumors
NCT02326025PHASE1COMPLETEDA Study of Olaratumab and Doxorubicin in Participants With Advanced Soft Tissue Sarcoma
NCT02377752PHASE1COMPLETEDA Study of Olaratumab in Japanese Participants With Advanced Cancer
NCT02677116PHASE1COMPLETEDA Study of Olaratumab Alone and in Combination With Standard Chemotherapies in Children With Cancer
NCT02783599PHASE1COMPLETEDA Study of Olaratumab (LY3012207) in Participants With Soft Tissue Sarcoma
NCT03126591PHASE1COMPLETEDA Study of Olaratumab (LY3012207) Plus Pembrolizumab in Participants With Advanced or Metastatic Soft Tissue Sarcoma
NCT03283696PHASE1COMPLETEDA Study of Olaratumab (LY3012207), Doxorubicin, and Ifosfamide in Participants With Advanced or Metastatic Soft Tissue Sarcoma
NCT03437070PHASE1WITHDRAWNTrabectedin, Doxorubicin and Olaratumab in Patients With Metastatic or Recurrent Leiomyosarcoma
NCT03985722PHASE1UNKNOWNOlaratumab Plus Trabectedin in Advanced Soft-tissue Sarcoma Patients Soft-tissue Sarcoma Patients
NCT03994627Not specifiedAPPROVED_FOR_MARKETINGOlaratumab (LY3012207) Patient Access for Soft Tissue Sarcoma

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Molecules sharing ≥1 of this drug’s curated primary targets, merged from two biobtree sources and ranked by shared-target count, then clinical phase: ChEMBL clinical-stage candidates (development phase ≥2) and PubChem drug-class bioactivity (approved / known drugs acting on the target). Deduplicated by drug name; the drug’s own salt forms are excluded. Note: for a drug with few primary targets a shared-target match can reflect off-target / promiscuous binding rather than the same therapeutic mechanism — the phase ordering surfaces bona-fide therapeutics first.

70 molecules share ≥1 primary target. Top 70 by shared-target count:

MoleculeSourceStatusShared targets
AVAPRITINIBChEMBL + PubChemPhase 4 (approved)PDGFRA
PAZOPANIBChEMBL + PubChemPhase 4 (approved)PDGFRA
REGORAFENIBChEMBL + PubChemPhase 4 (approved)PDGFRA
AXITINIBChEMBLPhase 4 (approved)PDGFRA
BOSUTINIBChEMBLPhase 4 (approved)PDGFRA
CERITINIBChEMBLPhase 4 (approved)PDGFRA
DASATINIBChEMBLPhase 4 (approved)PDGFRA
ERLOTINIBChEMBLPhase 4 (approved)PDGFRA
FEDRATINIBChEMBLPhase 4 (approved)PDGFRA
IMATINIBChEMBLPhase 4 (approved)PDGFRA
INFIGRATINIBChEMBLPhase 4 (approved)PDGFRA
LENVATINIBChEMBLPhase 4 (approved)PDGFRA
MIDOSTAURINChEMBLPhase 4 (approved)PDGFRA
NILOTINIBChEMBLPhase 4 (approved)PDGFRA
NINTEDANIBChEMBLPhase 4 (approved)PDGFRA
NINTEDANIB ESYLATEChEMBLPhase 4 (approved)PDGFRA
PEXIDARTINIBChEMBLPhase 4 (approved)PDGFRA
PONATINIBChEMBLPhase 4 (approved)PDGFRA
QUIZARTINIBChEMBLPhase 4 (approved)PDGFRA
RIPRETINIBChEMBLPhase 4 (approved)PDGFRA
SORAFENIBChEMBLPhase 4 (approved)PDGFRA
SUNITINIBChEMBLPhase 4 (approved)PDGFRA
TIVOZANIBChEMBLPhase 4 (approved)PDGFRA
VANDETANIBChEMBLPhase 4 (approved)PDGFRA
ALVOCIDIBChEMBLPhase 3PDGFRA
BARASERTIBChEMBLPhase 3PDGFRA
BRIVANIBChEMBLPhase 3PDGFRA
CANERTINIBChEMBLPhase 3PDGFRA
CEDIRANIBChEMBLPhase 3PDGFRA
CRENOLANIBChEMBLPhase 3PDGFRA
DOVITINIBChEMBLPhase 3PDGFRA
IBCASERTIBChEMBLPhase 3PDGFRA
LESTAURTINIBChEMBLPhase 3PDGFRA
LINIFANIBChEMBLPhase 3PDGFRA
MASITINIBChEMBLPhase 3PDGFRA
MOTESANIBChEMBLPhase 3PDGFRA
OLVEREMBATINIBChEMBLPhase 3PDGFRA
PIMICOTINIBChEMBLPhase 3PDGFRA
RETASPIMYCINChEMBLPhase 3PDGFRA
SARACATINIBChEMBLPhase 3PDGFRA
SEMAXANIBChEMBLPhase 3PDGFRA
VATALANIBChEMBLPhase 3PDGFRA
VIMSELTINIBChEMBLPhase 3PDGFRA
AMUVATINIBChEMBLPhase 2PDGFRA
AT-9283ChEMBLPhase 2PDGFRA
BEMCENTINIBChEMBLPhase 2PDGFRA
BMS-777607ChEMBLPhase 2PDGFRA
CENISERTIBChEMBLPhase 2PDGFRA
CEP-11981ChEMBLPhase 2PDGFRA
DEFOSBARASERTIBChEMBLPhase 2PDGFRA
DORAMAPIMODChEMBLPhase 2PDGFRA
ELLIPTINIUMChEMBLPhase 2PDGFRA
ENMD-2076ChEMBLPhase 2PDGFRA
FORETINIBChEMBLPhase 2PDGFRA
ILORASERTIBChEMBLPhase 2PDGFRA
MIVAVOTINIBChEMBLPhase 2PDGFRA
NEFLAMAPIMODChEMBLPhase 2PDGFRA
OSI-632ChEMBLPhase 2PDGFRA
R-406ChEMBLPhase 2PDGFRA
RAF-265ChEMBLPhase 2PDGFRA
REBASTINIBChEMBLPhase 2PDGFRA
SOTULETINIBChEMBLPhase 2PDGFRA
SU-014813ChEMBLPhase 2PDGFRA
TANDUTINIBChEMBLPhase 2PDGFRA
TOZASERTIBChEMBLPhase 2PDGFRA
AfatinibPubChemApprovedPDGFRA
CrizotinibPubChemApprovedPDGFRA
GefitinibPubChemApprovedPDGFRA
IdelalisibPubChemApprovedPDGFRA
SelumetinibPubChemApprovedPDGFRA

About this page

Generated deterministically by Sugi Atlas from primary biomedical databases via BioBTree. Every record on this page traces to a primary source.

Generated
Atlas version
v1.1.4
BioBTree
v2.0.2

Sources 30

This page pulls from 30 datasets indexed by BioBTree:

chebichembl_activitychembl_moleculechembl_targetcivic_evidenceclingen_dosageclinical_trialsdepmapefoensemblentrezgogoparentgtopdbgtopdb_interactiongtopdb_ligandhgncmeshmondomsigdbpatent_compoundpharmgkbpharmgkb_guidelinepubchempubchem_activityreactomereactomeparentrefseqtranscriptuniprot